TARS.US Tarsus Pharmaceuticals Inc

Healthcare Pharmaceuticals USA Stocks
78.20 USD
Close of Nov 18, 2026
53.89 91.53
Market cap
USD 3.86B
P/E
-
P/B
37.29x
ROE
-889.3%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.

Is TARS.US undervalued?

Graham number

The Graham number of Tarsus Pharmaceuticals Inc cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Tarsus Pharmaceuticals Inc fundamental analysis

No fundamental analysis for Tarsus Pharmaceuticals Inc yet.

Tarsus Pharmaceuticals Inc stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Tarsus Pharmaceuticals Inc

Tarsus Pharmaceuticals, Inc., a commercial stage biopharmaceutical company, focuses on the development and commercialization of therapeutic candidates for eye care in the United States. The company offers XDEMVY, a lotilaner ophthalmic solution for the treatment of demodex blepharitis caused by the infestation of Demodex mites. It sells its products to specialty pharmacies and distributors, as well as clinics, hospitals, pharmacies, and federal healthcare programs. The compa…

Full company profile